Literature DB >> 22125107

[Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood].

Piotr Glinicki1, Wojciech Jeske.   

Abstract

Chromogranin A (CgA) is regarded as a major, nonspecific neuroendocrine tumour (NET) marker. The results of CgA blood concentration, however, may actually be influenced by various factors or coexisting pathological conditions. Among the factors causing a substantial increase of the blood CgA concentration are: treatment with proton-pump inhibitors or H2 -receptor blockers, chronic atrophic gastritis (type A), impaired renal function, prostate cancer and BPH, and rheumatoid arthritis with high level of RF IgM. In addition, the sort of investigated biological material (whether it is serum or plasma) is of importance. There are also many conditions which may have a moderate or little influence on the concentration of CgA, among them are: inflammatory bowel disease (ulcerative colitis and Crohn's disease), deteriorating liver function, untreated essential hypertension, heart failure, hypercortisolism, pregnancy, and, in some subjects, ingestion of a meal. Proper assessment of the CgA results requires detailed knowledge about various factors, drugs, and pathological conditions influencing its concentration in blood.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22125107

Source DB:  PubMed          Journal:  Endokrynol Pol        ISSN: 0423-104X            Impact factor:   1.582


  2 in total

Review 1.  Circulating Neuroendocrine Tumor Biomarkers: Past, Present and Future.

Authors:  Paweł Komarnicki; Jan Musiałkiewicz; Alicja Stańska; Adam Maciejewski; Paweł Gut; George Mastorakos; Marek Ruchała
Journal:  J Clin Med       Date:  2022-09-21       Impact factor: 4.964

2.  Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.

Authors:  Masayuki Hijioka; Tetsuhide Ito; Hisato Igarashi; Nao Fujimori; Lingaku Lee; Taichi Nakamura; Robert T Jensen; Ryoichi Takayanagi
Journal:  Cancer Sci       Date:  2014-10-18       Impact factor: 6.716

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.